Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21440803 | 0.81 | USP2 (0.49) | CHRM2CNR2PARP1SMN1; SMN2 | |
| SCHEMBL3947809 | 0.78 | MGLL (0.62) | CHRM2CNR2L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL1806537 | 0.74 | CHRM2 (0.47) | CHRM2CNR2PARP1 | |
| SCHEMBL3946115 | 0.74 | L3MBTL1 (0.55) | PARP1L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL27787042 | 0.74 | KDM4E (0.50) | L3MBTL3L3MBTL1TP53BP1KDM4EALDH1A1 | |
| SCHEMBL8445412 | 0.73 | KMT2A (0.69) | CHRM2L3MBTL3L3MBTL1TP53BP1KDM4E | |
| SCHEMBL5820226 | 0.71 | HTR3A (0.58) | PARP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15880069 | 0.71 | HCRTR2 (0.52) | CHRM2CNR2PARP1 | |
| SCHEMBL3946070 | 0.70 | KDM4E (0.47) | L3MBTL3L3MBTL1TP53BP1KDM4EALDH1A1 | |
| SCHEMBL3947416 | 0.70 | KDM4E (0.47) | CNR2L3MBTL3L3MBTL1TP53BP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118057-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2008095820-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095820-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | HRH4, HRH3, H1-3 | CHRM2 30/4885CNR2 48/4885PARP1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.